Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation

We compared serious early and late events experienced by 2726 bone marrow (BM) and 6768 peripheral blood stem cell (PBSC) donors who underwent collection of PBSC or BM between 2004 and 2009 as part of a prospective study through the National Marrow Donor Program. Standardized FDA definitions for ser...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Pulsipher, Michael A., Chitphakdithai, Pintip, Logan, Brent R., Navarro, Willis H., Levine, John E., Miller, John P., Shaw, Bronwen E., O’Donnell, Paul V., Majhail, Navneet S., Confer, Dennis L.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2014
Materias:
Transfusion Medicine
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4047500/
https://ncbi.nlm.nih.gov/pubmed/24735965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-12-542464
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares